Read by QxMD icon Read

long acting release octreotide in short bowel

George C Nikou, Christos Toumpanakis, Christina Katsiari, Dionisios Charalambopoulos, Petros P Sfikakis
BACKGROUND: Symptoms associated with small intestinal involvement in patients with systemic sclerosis (SSc) are usually severe and resistant to treatment. OBJECTIVES: To assess the safety and efficacy of octreotide in refractory small intestinal disease complicating SSc. METHODS: Seven female patients (aged from 37 to 64 years old) with SSc were included in the study. All of them had symptoms compatible with small bowel pathology, nonresponding to several prokinetic agents...
June 2007: Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases
Efraín Gómez-Herrera, Oscar Alejandro Farías-Llamas, José Luis Gutiérrez-de la Rosa, José Manuel Hermosillo-Sandoval
INTRODUCTION: Short bowel syndrome (SBS) comprises sequelaes of nutrient, fluid, and weight loss that occur subsequent to greatly reduced functional surface area of small intestine. Maintenance of fluid and electrolyte homeostasis in patients with SBS is often difficult; additional intravenous (i.v.) fluid and electrolytes are often required to cover unabsorbed secretory losses. The recent development of the synthetic long-acting release (LAR) depot octapeptide analog, octreotide, has rendered somatostatin therapy a practical alternative in patients with SBS who have become entrapped in a vicious cycle with chronic dehydration, thirst, and excessive fluid or food consumption...
September 2004: Cirugia y Cirujanos
V Nehra, M Camilleri, D Burton, L Oenning, D G Kelly
OBJECTIVES: The aim of this study was to assess the effects of the long-acting release (LAR) depot octreotide preparation Sandostatin LAR Depot on stool water and electrolyte losses, fecal fat excretion, and GI transit in patients with short bowel syndrome. METHODS: We performed a 15-wk, prospective, open-label study of intramuscular (i.m.) Sandostatin LAR Depot, 20 mg, at 0, 3, 7, and 11 wk. Balance studies were performed before and at the end of the 15-wk study...
May 2001: American Journal of Gastroenterology
M A Crook, A Steger
Octreotide is a long-acting analog of somatostatin, a hypothalamic release-inhibiting hormone. It is sometimes used therapeutically to relieve symptoms associated with acromegaly and gastroenteropancreatic endocrine tumors. It has also been used in the treatment of short-bowel syndrome and gastrointestinal and biliary fistulae. We report a patient with biliary leakage due to Marizzi's syndrome treated with total parenteral nutrition and octreotide who developed abnormal liver function tests that improved when the two treatments were stopped...
February 2001: Nutrition
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"